|
Age at pregnancy (year), Median [IQR]
|
29 [25–33] (1 unknown case)
|
31 [29–34]
|
27 [26–30] (1 unknown case)
|
|
Parity, %
|
|
Primigravida
|
50 (8/16)
|
80 (8/10)
|
69.2 (9/13)
|
|
Multigravida
|
50 (8/16)
|
20 (2/10)
|
30.8 (4/13)
|
|
Unknown, number
|
10
|
3
|
1
|
|
Timing of flare, %
|
|
1st trimester
|
24 (6/25)
|
23.1 (3/13)
|
–
|
|
2nd trimester
|
52 (13/25)
|
38.5 (5/13)
|
–
|
|
3rd trimester
|
8 (2/25)
|
7.7 (1/13)
|
–
|
|
Postpartum
|
16 (4/25)
|
30.8 (4/13)
|
–
|
|
Unknown, number
|
1
|
0
|
–
|
|
Major symptoms and complications, %
|
|
Fever
|
95.7 (22/23)
|
70 (7/10)
|
–
|
|
Arthralgia, Arthritis
|
91.3 (21/23)
|
60 (6/10)
|
–
|
|
Erythema, Rash
|
78.3 (18/23)
|
50 (5/10)
|
–
|
|
Sore throat
|
65.2 (15/23)
|
30 (3/10)
|
–
|
|
Lymphadenopathy
|
60.9 (14/23)
|
10 (1/10)
|
–
|
|
Hepatomegaly, Liver dysfunction
|
34.8 (8/23)
|
30 (3/10)
|
–
|
|
Splenomegaly
|
34.8 (8/23)
|
10 (1/10)
|
–
|
|
HLH
|
8.7 (2/23)
|
10 (1/10)
|
–
|
|
Unknown, number
|
3
|
3
|
–
|
|
Major treatment, %
|
|
Corticosteroid
|
82.6 (19/23)
|
69.2 (9/13)
|
28.6 (4/14)
|
|
Anakinra
|
13.0 (3/23)
|
7.7 (1/13)
|
28.6 (4/14)
|
|
IVIg
|
17.4 (4/23)
|
7.7 (1/13)
|
7.1 (1/14)
|
|
NSAIDs
|
21.7 (5/23)
|
7.7 (1/13)
|
14.3 (2/14)
|
|
HCQ
|
4.3 (1/23)
|
15.4 (2/13)
|
7.1 (1/14)
|
|
No medication
|
–
|
–
|
57.1 (8/14)
|
|
Unknown, number
|
3
|
0
|
0
|
|
Delivery, %
|
|
Transvaginal
|
66.7 (12/18)
|
50 (4/8)
|
62.5 (5/8)
|
|
Cesarean section
|
22.2 (4/18)
|
50 (4/8)
|
25 (2/8)
|
|
Abortion
|
11.1 (2/18)
|
0 (0/8)
|
12.5 (1/8)
|
|
Unknown, number
|
8
|
5
|
6
|
|
Major obstetrical and perinatal complications, %
|
|
Preterm birth
|
32 (8/25)
|
33.3 (4/12)
|
16.7 (2/12)
|
|
IUGR
|
8 (2/25)
|
41.7 (5/12)
|
8.3 (1/12)
|
|
pPROM
|
12 (3/25)
|
8.3 (1/12)
|
8.3 (1/12)
|
|
No major complication
|
48 (12/25)
|
41.7 (5/12)
|
50 (6/12)
|
|
Others, number
|
2 for OHD, 1 for neonatal HLH, 1 for preeclampsia, and 1 for neonatal death for IRDS
|
1 for GDM, and 1 for OHD
|
1 for neonatal HLH, 1 for GDM, and 1 for HDP
|
|
Unknown, number
|
1
|
1
|
2
|
